Literature DB >> 18768302

Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.

Matthew E Falagas1, Petros I Rafailidis, Dimitrios K Matthaiou, Simona Virtzili, Dimitra Nikita, Argyris Michalopoulos.   

Abstract

We describe the characteristics and outcome of pandrug-resistant (PDR) Gram-negative bacterial infections (23 Klebsiella pneumoniae isolates, 3 Pseudomonas aeruginosa and 3 Acinetobacter baumannii) of hospitalised patients at a tertiary-care centre (1 January 2006-31 May 2007). The site of infection was central venous catheter-related in 5 of 24 patients with clinical infection, bacteraemia in 5, the respiratory system in 5, surgical site in 5, the urinary system in 2, the ascitic fluid in 1 and the central nervous system in one. Twenty of 24 patients with infection received an antibiotic regimen containing colistin (in combination with meropenem in 8 patients). The overall in-hospital mortality was 41.7% (10/24); 8 patients died because of the PDR infection (infection-related mortality 33.3%). Significant co-morbidity was present not only in the patients who died but also in survivors. PDR Gram-negative bacterial infections are associated with considerable mortality, although not as high as expected given the fact that the isolates were resistant to all tested antibiotics, including polymyxins. Antibiotics that are ineffective in vitro may prove life-saving for some of these patients, especially combination regimens containing colistin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768302     DOI: 10.1016/j.ijantimicag.2008.05.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  52 in total

Review 1.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

2.  White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

Authors: 
Journal:  Clin Infect Dis       Date:  2012-08-13       Impact factor: 9.079

Review 3.  Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?

Authors:  Cédric Abat; Pierre-Edouard Fournier; Marie-Thérèse Jimeno; Jean-Marc Rolain; Didier Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-28       Impact factor: 3.267

Review 4.  Structure--activity relationships of polymyxin antibiotics.

Authors:  Tony Velkov; Philip E Thompson; Roger L Nation; Jian Li
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

5.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 6.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 7.  Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.

Authors:  Carl Llor; Lars Bjerrum
Journal:  Ther Adv Drug Saf       Date:  2014-12

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

10.  Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Hee Ji Lee; Phillip J Bergen; Jurgen B Bulitta; Brian Tsuji; Alan Forrest; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.